Upcoming webinar: Genomics 101

The Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are pleased to invite you to a webinar about genomics. This webinar is primarily targeted at Canadian clinicians, academics and trainees with an interest in neuromuscular disease. NMD4C and MDC are providing organisational and technical support, and this is an independent clinical/academic webinar with no industry sponsorship.

This webinar is CME-accredited. The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

If you have any questions, please email


Register HERE


Topics and speakers:

Introduction

Dr. James Dowling (NMD4C Steering Committee Member)

Genetic counselling: What do families need to know and when?

Lauren Brady

Testing platforms

Kim Amburgey (NMD4C Collaborator)

Non-genetic diagnostics in the genomics era

Dr. Hernan Gonorazky

Variants of unknown significance

Dr. James Dowling (NMD4C Steering Committee Member)


Learning objectives:

  1. Compare different genetic technologies and select the best test for your patient
  2. Gain a better understanding of result interpretation and variants of unknown significance
  3. Recognize opportunities for implementing genetic counselling into patient care
  4. Identify the appropriate use of non-genetic diagnostics tests in the genomic era
file

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.